Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2023.

Full year 2023 total revenues increased by 19% to US$245.3 million
Record fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to US$227.1 million
Strong start to Joenja® (leniolisib) launch with 81 patients on paid therapy in the U.S. nine months following launch and full year 2023 revenues of US$18.2 million
Overall cash and marketable securities increased to US$215.0 million at the end of 2023 from US$208.7 million at the end of 2022
Progressed leniolisib development for APDS in additional geographies and for pediatric patients, and leniolisib indication expansion to primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3K? signaling
2024 total revenue guidance of US$280 million – US$295 million (14% – 20% growth)

go to for more
https://www.pharming.com/sites/default/files/imce/Press%20releases/Pharming%20Group%204Q%202023%20financial%20results_EN_14MAR2024_final.pdf